Hakutulokset - Günter Fingerle‐Rowson

Tarkenna hakua
  1. 1
    A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies

    A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies Tekijä Kensei Tobinai, Christian Klein, Naoko Oya, Günter Fingerle‐Rowson

    Julkaistu 2016
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    Selective depletion of CD14+ CD16+ monocytes by glucocorticoid therapy

    Selective depletion of CD14+ CD16+ monocytes by glucocorticoid therapy Tekijä Günter Fingerle‐Rowson, Matthias Angstwurm, R Andreesen, H.W.L. Ziegler-Heitbrock

    Julkaistu 1998
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response

    Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response Tekijä Robert A. Mitchell, Hong Liao, Jason Chesney, Günter Fingerle‐Rowson, John A. Baugh, John R. David, Richard Bucala

    Julkaistu 2001
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression

    Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression Tekijä Ramona Schulz, Natalia Marchenko, Lena Holembowski, Günter Fingerle‐Rowson, Marina Pešić, Lars Zender, Matthias Dobbelstein, Ute M. Moll

    Julkaistu 2012
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    Regulation of Macrophage Migration Inhibitory Factor Expression by Glucocorticoids in Vivo

    Regulation of Macrophage Migration Inhibitory Factor Expression by Glucocorticoids in Vivo Tekijä Günter Fingerle‐Rowson, Peter D. Koch, Rachel Bikoff, Xinchun Lin, Christine N. Metz, Firdaus S. Dhabhar, Andreas Meinhardt, Richard Bucala

    Julkaistu 2003
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  6. 6
    Macrophage Migration Inhibitory Factor and CD74 Regulate Macrophage Chemotactic Responses via MAPK and Rho GTPase

    Macrophage Migration Inhibitory Factor and CD74 Regulate Macrophage Chemotactic Responses via MAPK and Rho GTPase Tekijä Huapeng Fan, Pam Hall, Leilani L. Santos, Julia L. Gregory, Günter Fingerle‐Rowson, Richard Bucala, Eric F. Morand, Michael J. Hickey

    Julkaistu 2011
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  7. 7
    Macrophage Migration Inhibitory Factor Inhibits the Antiinflammatory Effects of Glucocorticoids via Glucocorticoid‐Induced Leucine Zipper

    Macrophage Migration Inhibitory Factor Inhibits the Antiinflammatory Effects of Glucocorticoids via Glucocorticoid‐Induced Leucine Zipper Tekijä Huapeng Fan, Wenping Kao, Yuan Yang, Ran Gu, James Harris, Günter Fingerle‐Rowson, Richard Bucala, Devi Ngo, Élaine Beaulieu, Eric F. Morand

    Julkaistu 2014
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  8. 8
    The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting

    The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting Tekijä Günter Fingerle‐Rowson, Oleksi Petrenko, Christine N. Metz, Thomas G. Forsthuber, Robert A. Mitchell, Ralf Huss, Ute M. Moll, Werner Müller, Richard Bucala

    Julkaistu 2003
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  9. 9
    Macrophage migration inhibitory factor regulates neutrophil chemotactic responses in inflammatory arthritis in mice

    Macrophage migration inhibitory factor regulates neutrophil chemotactic responses in inflammatory arthritis in mice Tekijä Leilani L. Santos, Huapeng Fan, Pam Hall, Devi Ngo, Charles R. Mackay, Günter Fingerle-Rowson, Richard Bucala, Michael J. Hickey, Eric F. Morand

    Julkaistu 2010
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  10. 10
    Critical role for macrophage migration inhibitory factor (MIF) in Ross River virus-induced arthritis and myositis

    Critical role for macrophage migration inhibitory factor (MIF) in Ross River virus-induced arthritis and myositis Tekijä Lara J. Herrero, Michelle Nelson, Anon Srikiatkhachorn, Ran Gu, Surapee Anantapreecha, Günter Fingerle‐Rowson, Richard Bucala, Eric F. Morand, Leilani L. Santos, Suresh Mahalingam

    Julkaistu 2011
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  11. 11
    The vestigial enzyme D-dopachrome tautomerase protects the heart against ischemic injury

    The vestigial enzyme D-dopachrome tautomerase protects the heart against ischemic injury Tekijä Dake Qi, Kwame Atsina, Lintao Qu, Xiaoyue Hu, Xiaohong Wu, Bin Xu, Marta Piecychna, Lin Leng, Günter Fingerle‐Rowson, Jiasheng Zhang, Richard Bucala, Lawrence H. Young

    Julkaistu 2014
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  12. 12
    Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis

    Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis Tekijä Ran Gu, Leilani L. Santos, Devi Ngo, Huapeng Fan, Preetinder P. Singh, Günter Fingerle‐Rowson, Richard Bucala, Jiake Xu, Julian M.W. Quinn, Eric F. Morand

    Julkaistu 2015
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  13. 13
    Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study

    Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study Tekijä Valentin Goede, Kirsten Fischer, Anja Engelke, Rudolf Schlag, Stéphane Leprêtre, Luis Felipe Casado Montero, Marco Montillo, Chris Fegan, Elina Asikanius, K. Humphrey, Günter Fingerle‐Rowson, Michael Hallek

    Julkaistu 2015
    Hae kokoteksti
    Carta
    Lisää suosikkeihin
    Tallennettuna:
  14. 14
    Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions

    Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions Tekijä Ciara L. Freeman, Franck Morschhauser, Laurie H. Sehn, Mark Dixon, Richard Houghton, Thierry Lamy, Günter Fingerle‐Rowson, Elisabeth Wassner-Fritsch, John G. Gribben, Michael Hallek, Gilles Salles, Guillaume Cartron

    Julkaistu 2015
    Hae kokoteksti Hae kokoteksti
    Carta
    Lisää suosikkeihin
    Tallennettuna:
  15. 15
    MIF but not MIF-2 recruits inflammatory macrophages in an experimental polymicrobial sepsis model

    MIF but not MIF-2 recruits inflammatory macrophages in an experimental polymicrobial sepsis model Tekijä Pathricia V. Tilstam, Wibke Schulte, Thomas Holowka, Bong‐Sung Kim, Jessica Nouws, Maor Sauler, Marta Piecychna, Georgios Pantouris, Elias Lolis, Lin Leng, Jürgen Bernhagen, Günter Fingerle‐Rowson, Richard Bucala

    Julkaistu 2021
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  16. 16
    Macrophage Migration Inhibitory Factor (MIF) Enzymatic Activity and Lung Cancer

    Macrophage Migration Inhibitory Factor (MIF) Enzymatic Activity and Lung Cancer Tekijä Leona Mawhinney, Michelle E. Armstrong, Ciaran O’Reilly, Richard Bucala, Lin Leng, Günter Fingerle‐Rowson, Darren Fayne, Michael P. Keane, Aisling Tynan, Lewena Maher, Gordon Cooke, David G. Lloyd, Helen Conroy, Seamas C. Donnelly

    Julkaistu 2014
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  17. 17
    Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study

    Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study Tekijä Christopher R. Bolen, Magdalena Klánová, Marek Trněný, Laurie H. Sehn, Jie He, Jing Tong, Joseph N. Paulson, Eugene Kim, Umberto Vitolo, Alice Di Rocco, Günter Fingerle‐Rowson, Tina Nielsen, Georg Lenz, Mikkel Z. Oestergaard

    Julkaistu 2019
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  18. 18
    Macrophage Migration Inhibitory Factor Enzymatic Activity, Lung Inflammation, and Cystic Fibrosis

    Macrophage Migration Inhibitory Factor Enzymatic Activity, Lung Inflammation, and Cystic Fibrosis Tekijä Huzaifa Adamali, Michelle E. Armstrong, Anne Marie McLaughlin, Gordon Cooke, Edward F. McKone, Christine Costello, Charles G. Gallagher, Lin Leng, John A. Baugh, Günter Fingerle‐Rowson, Richard Bucala, Paul McLoughlin, Seamas C. Donnelly

    Julkaistu 2012
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  19. 19
    Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial

    Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Rando... Tekijä Sebastian Böttcher, Matthias Ritgen, Kirsten Fischer, Stephan Stilgenbauer, Raymonde M. Busch, Günter Fingerle‐Rowson, Anna Maria Fink, Andreas Bühler, Thorsten Zenz, Michael Wenger, Myriam Mendila, Clemens‐Martin Wendtner, Barbara Eichhorst, Hartmut Döhner, Michael Hallek, Michael Kneba

    Julkaistu 2012
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  20. 20
    A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL

    A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL Tekijä Natalie Dimier, Paul Delmar, Carol Ward, Rodica Morariu-Zamfir, Günter Fingerle‐Rowson, Jasmin Bahlo, Kirsten Fischer, Barbara Eichhorst, Valentin Goede, Jacques J. M. van Dongen, Matthias Ritgen, Sebastian Böttcher, Anton W. Langerak, Michael Kneba, Michael Hallek

    Julkaistu 2017
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: